OXGR1 is a candidate disease gene for human calcium oxalate nephrolithiasis
Copyright © 2022 American College of Medical Genetics and Genomics. Published by Elsevier Inc. All rights reserved..
PURPOSE: Nephrolithiasis (NL) affects 1 in 11 individuals worldwide, leading to significant patient morbidity. NL is associated with nephrocalcinosis (NC), a risk factor for chronic kidney disease. Causative genetic variants are detected in 11% to 28% of NL and/or NC, suggesting that additional NL/NC-associated genetic loci await discovery. Therefore, we employed genomic approaches to discover novel genetic forms of NL/NC.
METHODS: Exome sequencing and directed sequencing of the OXGR1 locus were performed in a worldwide NL/NC cohort. Putatively deleterious, rare OXGR1 variants were functionally characterized.
RESULTS: Exome sequencing revealed a heterozygous OXGR1 missense variant (c.371T>G, p.L124R) cosegregating with calcium oxalate NL and/or NC disease in an autosomal dominant inheritance pattern within a multigenerational family with 5 affected individuals. OXGR1 encodes 2-oxoglutarate (α-ketoglutarate [AKG]) receptor 1 in the distal nephron. In response to its ligand AKG, OXGR1 stimulates the chloride-bicarbonate exchanger, pendrin, which also regulates transepithelial calcium transport in cortical connecting tubules. Strong amino acid conservation in orthologs and paralogs, severe in silico prediction scores, and extreme rarity in exome population databases suggested that the variant was deleterious. Interrogation of the OXGR1 locus in 1107 additional NL/NC families identified 5 additional deleterious dominant variants in 5 families with calcium oxalate NL/NC. Rare, potentially deleterious OXGR1 variants were enriched in patients with NL/NC compared with Exome Aggregation Consortium controls (χ2 = 7.117, P = .0076). Wild-type OXGR1-expressing Xenopus oocytes exhibited AKG-responsive Ca2+ uptake. Of 5 NL/NC-associated missense variants, 5 revealed impaired AKG-dependent Ca2+ uptake, demonstrating loss of function.
CONCLUSION: Rare, dominant loss-of-function OXGR1 variants are associated with recurrent calcium oxalate NL/NC disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Genetics in medicine : official journal of the American College of Medical Genetics - 25(2023), 3 vom: 01. März, Seite 100351 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Majmundar, Amar J [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.03.2023 Date Revised 02.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.gim.2022.11.019 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350829608 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350829608 | ||
| 003 | DE-627 | ||
| 005 | 20240302232029.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.gim.2022.11.019 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1314.xml |
| 035 | |a (DE-627)NLM350829608 | ||
| 035 | |a (NLM)36571463 | ||
| 035 | |a (PII)S1098-3600(22)01038-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Majmundar, Amar J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a OXGR1 is a candidate disease gene for human calcium oxalate nephrolithiasis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.03.2023 | ||
| 500 | |a Date Revised 02.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 American College of Medical Genetics and Genomics. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a PURPOSE: Nephrolithiasis (NL) affects 1 in 11 individuals worldwide, leading to significant patient morbidity. NL is associated with nephrocalcinosis (NC), a risk factor for chronic kidney disease. Causative genetic variants are detected in 11% to 28% of NL and/or NC, suggesting that additional NL/NC-associated genetic loci await discovery. Therefore, we employed genomic approaches to discover novel genetic forms of NL/NC | ||
| 520 | |a METHODS: Exome sequencing and directed sequencing of the OXGR1 locus were performed in a worldwide NL/NC cohort. Putatively deleterious, rare OXGR1 variants were functionally characterized | ||
| 520 | |a RESULTS: Exome sequencing revealed a heterozygous OXGR1 missense variant (c.371T>G, p.L124R) cosegregating with calcium oxalate NL and/or NC disease in an autosomal dominant inheritance pattern within a multigenerational family with 5 affected individuals. OXGR1 encodes 2-oxoglutarate (α-ketoglutarate [AKG]) receptor 1 in the distal nephron. In response to its ligand AKG, OXGR1 stimulates the chloride-bicarbonate exchanger, pendrin, which also regulates transepithelial calcium transport in cortical connecting tubules. Strong amino acid conservation in orthologs and paralogs, severe in silico prediction scores, and extreme rarity in exome population databases suggested that the variant was deleterious. Interrogation of the OXGR1 locus in 1107 additional NL/NC families identified 5 additional deleterious dominant variants in 5 families with calcium oxalate NL/NC. Rare, potentially deleterious OXGR1 variants were enriched in patients with NL/NC compared with Exome Aggregation Consortium controls (χ2 = 7.117, P = .0076). Wild-type OXGR1-expressing Xenopus oocytes exhibited AKG-responsive Ca2+ uptake. Of 5 NL/NC-associated missense variants, 5 revealed impaired AKG-dependent Ca2+ uptake, demonstrating loss of function | ||
| 520 | |a CONCLUSION: Rare, dominant loss-of-function OXGR1 variants are associated with recurrent calcium oxalate NL/NC disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Alpha-ketoglutarate | |
| 650 | 4 | |a Calcium oxalate | |
| 650 | 4 | |a Genetics | |
| 650 | 4 | |a Nephrolithiasis | |
| 650 | 7 | |a Calcium Oxalate |2 NLM | |
| 650 | 7 | |a 2612HC57YE |2 NLM | |
| 650 | 7 | |a Sulfate Transporters |2 NLM | |
| 650 | 7 | |a OXGR1 protein, human |2 NLM | |
| 650 | 7 | |a Receptors, Purinergic P2 |2 NLM | |
| 700 | 1 | |a Widmeier, Eugen |e verfasserin |4 aut | |
| 700 | 1 | |a Heneghan, John F |e verfasserin |4 aut | |
| 700 | 1 | |a Daga, Ankana |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Chen-Han Wilfred |e verfasserin |4 aut | |
| 700 | 1 | |a Buerger, Florian |e verfasserin |4 aut | |
| 700 | 1 | |a Hugo, Hannah |e verfasserin |4 aut | |
| 700 | 1 | |a Ullah, Ihsan |e verfasserin |4 aut | |
| 700 | 1 | |a Amar, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Ottlewski, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Braun, Daniela A |e verfasserin |4 aut | |
| 700 | 1 | |a Jobst-Schwan, Tilman |e verfasserin |4 aut | |
| 700 | 1 | |a Lawson, Jennifer A |e verfasserin |4 aut | |
| 700 | 1 | |a Zahoor, Muhammad Yasir |e verfasserin |4 aut | |
| 700 | 1 | |a Rodig, Nancy M |e verfasserin |4 aut | |
| 700 | 1 | |a Tasic, Velibor |e verfasserin |4 aut | |
| 700 | 1 | |a Nelson, Caleb P |e verfasserin |4 aut | |
| 700 | 1 | |a Khaliq, Shagufta |e verfasserin |4 aut | |
| 700 | 1 | |a Schönauer, Ria |e verfasserin |4 aut | |
| 700 | 1 | |a Halbritter, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Sayer, John A |e verfasserin |4 aut | |
| 700 | 1 | |a Fathy, Hanan M |e verfasserin |4 aut | |
| 700 | 1 | |a Baum, Michelle A |e verfasserin |4 aut | |
| 700 | 1 | |a Shril, Shirlee |e verfasserin |4 aut | |
| 700 | 1 | |a Mane, Shrikant |e verfasserin |4 aut | |
| 700 | 1 | |a Alper, Seth L |e verfasserin |4 aut | |
| 700 | 1 | |a Hildebrandt, Friedhelm |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Genetics in medicine : official journal of the American College of Medical Genetics |d 1997 |g 25(2023), 3 vom: 01. März, Seite 100351 |w (DE-627)NLM097536970 |x 1530-0366 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2023 |g number:3 |g day:01 |g month:03 |g pages:100351 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.gim.2022.11.019 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2023 |e 3 |b 01 |c 03 |h 100351 | ||